A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography.
Adipose Tissue
/ diagnostic imaging
Aged
Algorithms
Case-Control Studies
Computed Tomography Angiography
Coronary Artery Disease
/ diagnostic imaging
Female
Follow-Up Studies
Gene Expression Profiling
/ methods
Genetic Markers
Humans
Machine Learning
Male
Middle Aged
Phenotype
Plaque, Atherosclerotic
/ diagnostic imaging
Risk Assessment
Transcriptome
Adipose tissue
Computed tomography
Coronary artery disease
Machine learning
Radiomics
Risk stratification
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
14 11 2019
14 11 2019
Historique:
received:
15
06
2019
revised:
14
07
2019
accepted:
06
08
2019
pubmed:
11
9
2019
medline:
6
10
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Coronary inflammation induces dynamic changes in the balance between water and lipid content in perivascular adipose tissue (PVAT), as captured by perivascular Fat Attenuation Index (FAI) in standard coronary CT angiography (CCTA). However, inflammation is not the only process involved in atherogenesis and we hypothesized that additional radiomic signatures of adverse fibrotic and microvascular PVAT remodelling, may further improve cardiac risk prediction. We present a new artificial intelligence-powered method to predict cardiac risk by analysing the radiomic profile of coronary PVAT, developed and validated in patient cohorts acquired in three different studies. In Study 1, adipose tissue biopsies were obtained from 167 patients undergoing cardiac surgery, and the expression of genes representing inflammation, fibrosis and vascularity was linked with the radiomic features extracted from tissue CT images. Adipose tissue wavelet-transformed mean attenuation (captured by FAI) was the most sensitive radiomic feature in describing tissue inflammation (TNFA expression), while features of radiomic texture were related to adipose tissue fibrosis (COL1A1 expression) and vascularity (CD31 expression). In Study 2, we analysed 1391 coronary PVAT radiomic features in 101 patients who experienced major adverse cardiac events (MACE) within 5 years of having a CCTA and 101 matched controls, training and validating a machine learning (random forest) algorithm (fat radiomic profile, FRP) to discriminate cases from controls (C-statistic 0.77 [95%CI: 0.62-0.93] in the external validation set). The coronary FRP signature was then tested in 1575 consecutive eligible participants in the SCOT-HEART trial, where it significantly improved MACE prediction beyond traditional risk stratification that included risk factors, coronary calcium score, coronary stenosis, and high-risk plaque features on CCTA (Δ[C-statistic] = 0.126, P < 0.001). In Study 3, FRP was significantly higher in 44 patients presenting with acute myocardial infarction compared with 44 matched controls, but unlike FAI, remained unchanged 6 months after the index event, confirming that FRP detects persistent PVAT changes not captured by FAI. The CCTA-based radiomic profiling of coronary artery PVAT detects perivascular structural remodelling associated with coronary artery disease, beyond inflammation. A new artificial intelligence (AI)-powered imaging biomarker (FRP) leads to a striking improvement of cardiac risk prediction over and above the current state-of-the-art.
Sections du résumé
BACKGROUND
Coronary inflammation induces dynamic changes in the balance between water and lipid content in perivascular adipose tissue (PVAT), as captured by perivascular Fat Attenuation Index (FAI) in standard coronary CT angiography (CCTA). However, inflammation is not the only process involved in atherogenesis and we hypothesized that additional radiomic signatures of adverse fibrotic and microvascular PVAT remodelling, may further improve cardiac risk prediction.
METHODS AND RESULTS
We present a new artificial intelligence-powered method to predict cardiac risk by analysing the radiomic profile of coronary PVAT, developed and validated in patient cohorts acquired in three different studies. In Study 1, adipose tissue biopsies were obtained from 167 patients undergoing cardiac surgery, and the expression of genes representing inflammation, fibrosis and vascularity was linked with the radiomic features extracted from tissue CT images. Adipose tissue wavelet-transformed mean attenuation (captured by FAI) was the most sensitive radiomic feature in describing tissue inflammation (TNFA expression), while features of radiomic texture were related to adipose tissue fibrosis (COL1A1 expression) and vascularity (CD31 expression). In Study 2, we analysed 1391 coronary PVAT radiomic features in 101 patients who experienced major adverse cardiac events (MACE) within 5 years of having a CCTA and 101 matched controls, training and validating a machine learning (random forest) algorithm (fat radiomic profile, FRP) to discriminate cases from controls (C-statistic 0.77 [95%CI: 0.62-0.93] in the external validation set). The coronary FRP signature was then tested in 1575 consecutive eligible participants in the SCOT-HEART trial, where it significantly improved MACE prediction beyond traditional risk stratification that included risk factors, coronary calcium score, coronary stenosis, and high-risk plaque features on CCTA (Δ[C-statistic] = 0.126, P < 0.001). In Study 3, FRP was significantly higher in 44 patients presenting with acute myocardial infarction compared with 44 matched controls, but unlike FAI, remained unchanged 6 months after the index event, confirming that FRP detects persistent PVAT changes not captured by FAI.
CONCLUSION
The CCTA-based radiomic profiling of coronary artery PVAT detects perivascular structural remodelling associated with coronary artery disease, beyond inflammation. A new artificial intelligence (AI)-powered imaging biomarker (FRP) leads to a striking improvement of cardiac risk prediction over and above the current state-of-the-art.
Identifiants
pubmed: 31504423
pii: 5554432
doi: 10.1093/eurheartj/ehz592
pmc: PMC6855141
doi:
Substances chimiques
Genetic Markers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3529-3543Subventions
Organisme : British Heart Foundation
ID : CH/16/1/32013
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/1/32013
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/15/32047
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/10/32859
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT103782AIA
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/13/56/30383
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701127
Pays : United Kingdom
Organisme : British Heart Foundation
ID : TG/16/3/32687
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/13/3/30183
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZH/4/588
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/5/34216
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/15/32047
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/55/30806
Pays : United Kingdom
Organisme : British Heart Foundation
ID : TG/16/3/32687
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur Heart J. 2018 Feb 14;39(7):508-579
pubmed: 29190377
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2151-9
pubmed: 25060790
Eur Heart J. 2019 Aug 14;40(31):2566-2584
pubmed: 31112213
Circulation. 2013 Jun 4;127(22):2209-21
pubmed: 23625959
Circ Res. 2005 May 13;96(9):939-49
pubmed: 15890981
Diabetes. 2015 Jun;64(6):2207-19
pubmed: 25552596
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Eur Heart J. 2018 Oct 7;39(38):3499-3507
pubmed: 30165610
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Lancet. 2015 Jun 13;385(9985):2383-91
pubmed: 25788230
J Thorac Imaging. 2018 Jan;33(1):26-34
pubmed: 28346329
JAMA. 2004 Jan 14;291(2):210-5
pubmed: 14722147
N Engl J Med. 2018 Sep 06;379(10):924-933
pubmed: 30145934
Lancet. 2018 Sep 15;392(10151):929-939
pubmed: 30170852
Diabetes. 2010 Nov;59(11):2755-63
pubmed: 20713685
J Am Coll Cardiol. 2012 Dec 18;60(24):2564-603
pubmed: 23182124
Eur Heart J Cardiovasc Imaging. 2018 Oct 1;19(10):1099-1106
pubmed: 30085023
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Nat Rev Cardiol. 2019 Feb;16(2):83-99
pubmed: 30287946
J Am Coll Cardiol. 2014 Aug 19;64(7):684-92
pubmed: 25125300
Circulation. 1975 Apr;51(4 Suppl):5-40
pubmed: 1116248
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Lancet. 2014 Feb 22;383(9918):705-13
pubmed: 24224999
Cell Metab. 2017 Mar 7;25(3):673-685
pubmed: 28215843
JMIR Med Inform. 2017 Jan 17;5(1):e3
pubmed: 28096065
J Cardiovasc Comput Tomogr. 2016 Jul-Aug;10(4):269-81
pubmed: 27318587
Eur Heart J. 2012 Jun;33(11):1309-17
pubmed: 22507974
J Cardiovasc Comput Tomogr. 2014 Sep-Oct;8(5):342-58
pubmed: 25301040
Sci Transl Med. 2017 Jul 12;9(398):
pubmed: 28701474
J Am Coll Cardiol. 2019 Jan 29;73(3):291-301
pubmed: 30678759
Eur Heart J. 2018 Sep 14;39(35):3281-3300
pubmed: 29790954
Eur Heart J Cardiovasc Imaging. 2019 Nov 1;20(11):1250-1258
pubmed: 30838375
J Clin Invest. 2017 Jan 3;127(1):74-82
pubmed: 28045400
Circ Cardiovasc Imaging. 2017 Dec;10(12):null
pubmed: 29233836